Compile Data Set for Download or QSAR
Report error Found 134 Enz. Inhib. hit(s) with all data for entry = 9938
TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501409(US11026937, Compound I-4)
Affinity DataIC50: 1.50E+3nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501454(US11026937, Compound I-49)
Affinity DataIC50: 1.50E+3nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501488(US11026937, Compound I-80)
Affinity DataIC50: 1.50E+3nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501484(US11026937, Compound I-76)
Affinity DataIC50: 1.50E+3nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501531(US11026937, Compound I-107)
Affinity DataIC50: 1.50E+3nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501444(US11026937, Compound I-34)
Affinity DataIC50: 1.50E+3nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501476(US11026937, Compound I-68)
Affinity DataIC50: 1.50E+3nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501425(US11026937, Compound I-22)
Affinity DataIC50: 1.50E+3nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501474(US11026937, Compound I-66)
Affinity DataIC50: 1.50E+3nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501423(US11026937, Compound I-20)
Affinity DataIC50: 1.50E+3nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501468(US11026937, Compound I-61)
Affinity DataIC50: 1.50E+3nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501466(US11026937, Compound I-60)
Affinity DataIC50: 1.50E+3nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501414(US11026937, Compound I-9)
Affinity DataIC50: 1.50E+3nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501459(US11026937, Compound I-53)
Affinity DataIC50: 1.50E+3nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501410(US11026937, Compound I-5)
Affinity DataIC50: 1.50E+3nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501456(US11026937, Compound I-50)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501453(US11026937, Compound I-48)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501452(US11026937, Compound I-47)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501451(US11026937, Compound I-46)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501450(US11026937, Compound I-45)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501449(US11026937, Compound I-44)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501448(US11026937, Compound I-43)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501446(US11026937, Compound I-41)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501428(US11026937, Compound I-28)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501475(US11026937, Compound I-67)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501473(US11026937, Compound I-65)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501472(US11026937, Compound I-64)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501470(US11026937, Compound I-63)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501464(US11026937, Compound I-58)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501462(US11026937, Compound I-56)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501461(US11026937, Compound I-55)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501460(US11026937, Compound I-54)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501458(US11026937, Compound I-52)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501482(US11026937, Compound I-74)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501481(US11026937, Compound I-73)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501479(US11026937, Compound I-71)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501478(US11026937, Compound I-70)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501477(US11026937, Compound I-69)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501523(US11026937, Compound I-99)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501509(US11026937, Compound I-86)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501538(US11026937, Compound I-114)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501530(US11026937, Compound I-106)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501529(US11026937, Compound I-105)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501528(US11026937, Compound I-104)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501558(US11026937, Compound I-131)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501557(US11026937, Compound I-130)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501556(US11026937, Compound I-129)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501549(US11026937, Compound I-125)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501547(US11026937, Compound I-123)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

TargetProtein-arginine deiminase type-4(Human)
Padlock Therapeutics

US Patent
LigandPNGBDBM501546(US11026937, Compound I-122)
Affinity DataIC50: 1.15E+4nMAssay Description:Assay buffer (as aforementioned): 100 mM Tris-HCl (pH 7.6), 2 mM DTT, 1 mM CaCl2Final concentrations:100 nM hPAD4 enzyme50 μM (8-fold sub-Km) su...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/29/2021
Entry Details
US Patent

Displayed 1 to 50 (of 134 total ) | Next | Last >>
Jump to: